Back to trial details

Intake questionnaire

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Applying to The University of Chicago Medical Center /ID# 262259 · Chicago, Illinois

Answer a few short questions to share with the research team.

0 of 4 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with Non-Small Cell Lung Cancer?
3. Are you currently pregnant or breastfeeding?
4. Are you able to travel to Chicago for study visits?